Date: 2011-06-24
Type of information: Granting of a patent
Product name: human embryonic stem-cell-derived retinal pigment epithelial cells
Compound: human embryonic stem-cell-derived retinal pigment epithelial cells
Therapeutic area: Ophtalmological diseases - Rare diseases
Action mechanism: cell therapy. This medicine is made up of retinal pigment epithelial cells. It is expected to be injected directly into the eye, under the retina, so that the cells can settle in the right part of the eye. Once implanted, the cells are expected to help the functioning of the retina.The retinal pigment epithelial cells in the medicine have been produced from embryonic stem cells. These are cells obtained from a human embryo that can develop into different types of cell.
Company: TMC Pharma Services (UK)
Disease: Stargardt’s disease
Latest news:
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE: 2011-06-24
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
